Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30909257 | 1.00 | HTR7 (0.44) | HTR7HTR2ADRD2HTR1AHTR6 | |
| Oxalic Acid SCHEMBL7484886 | 0.83 | DRD2 (0.44) | HTR7HTR2ADRD2HTR1ASLC6A4 | |
| Oxalic Acid SCHEMBL30909222 | 0.83 | DRD2 (0.44) | HTR7HTR2ADRD2HTR1ASLC6A4 | |
| Propiolic Acid SCHEMBL7482034 | 0.81 | HTR7 (0.47) | HTR7HTR2ADRD2HTR1AHTR6 | |
| Propiolic Acid SCHEMBL30909213 | 0.81 | HTR7 (0.47) | HTR7HTR2ADRD2HTR1AHTR6 | |
| SCHEMBL7483363 | 0.79 | HTR1A (0.52) | HTR7DRD2HTR1ASLC6A4 | |
| SCHEMBL30908884 | 0.79 | HTR1A (0.52) | HTR7DRD2HTR1ASLC6A4 | |
| SCHEMBL7482113 | 0.76 | HTR1A (0.57) | HTR7HTR2ADRD2HTR1AHTR6 | |
| Succinic Acid SCHEMBL7483217 | 0.76 | OPRM1 (0.48) | HTR7HTR2ADRD2HTR1DHTR1B | |
| SCHEMBL7484027 | 0.76 | HTR1D (0.52) | HTR7HTR2ADRD2HTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| EP-0733628-B9 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0733628-B1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-5962474-A | ANALGESICS; HEADACHES | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1996029075-A1 | 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0733628-A1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR7 13/4885HTR2A 12/4885DRD2 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.